Hepatic stellate cells modulate the differentiation of bone marrow mesenchymal stem cells into hepatocyte‐like cells

Deng, Xiangbing; Chen, Yue-Xiang; Zhang, Xin; Zhang, Junping; Yin, Chuan; Yue, Haiyan; Lin, Yong; Han, Ze‐Guang; Xie, Wei‐Fen

doi:10.1002/jcp.21481

Cited by 43 publications

(33 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deng et al 242 have analyzed the effect of co-culturing Kupffer cells and activated HeSCs with MSCs. They found that activated HeSCs in the presence of Kupffer cells express significant levels of HGF and induce differentiation of MSCs into hepatocyte-like cells that are able to produce glycogen deposition.…”

Section: Msc Signaling Mechanisms In Liver Fibrosismentioning

confidence: 99%

Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

Mesenchymal stem (stromal) cells (MSCs) are a source of circulating progenitors that are able to generate cells of all mesenchymal lineages and to cover cellular demands of injured tissues. The extent of their transdifferentiation plasticity remains controversial. Cells with MSC properties have been obtained from diverse tissues after purification and expansion in vitro. These cellular populations are heterogeneous and under certain conditions show pluripotent-like properties. MSCs present immunosuppressive and anti-inflammatory features and high migratory capacity toward inflamed or remodeling tissues. In this study we review available data regarding factors and signaling axes involved in the chemoattraction and engraftment of MSCs to an injured tissue or to a tissue undergoing active remodeling. Moreover, experimental evidence in support of uses of MSCs as vehicles of therapeutic genes is discussed. Because of its regenerative capacity and its particular immune properties, the liver is a good model to analyze the potential of MSCbased therapies. Finally, the potential application of MSCs and genetically modified MSCs in liver fibrosis and hepatocellular carcinoma (HCC) is proposed in view of available evidence.

show abstract

Section: Msc Signaling Mechanisms In Liver Fibrosismentioning

confidence: 99%

Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…It is generally believed that under the microenvironment of fibrosis or cirrhosis most transplanted stem cells differentiate into hepatocytes, and hepatic stellate cells by hepatic stellate cells [24] [54]. However, in a mouse model of liver fibrosis or cirrhosis with remarkable inflammation [23], the majority of injected stem cells differentiated into myofibroblasts, resulting in liver fibrosis being aggravated.…”

Section: Anti-inflammatory Treatmentmentioning

confidence: 99%

Therapeutic Strategies of Stem Cell Transplantation for Liver Cirrhosis

Fan¹

2017

View full text Add to dashboard Cite

Liver transplantation is widely regarded as the most effective therapy for end-stage liver diseases. However, stem cell-based therapy is being developed as a promising strategy which offers a number of benefits as it is minimally invasive and associated with low immunogenicity and low cost. This paper will review the major clinical issues surrounding the use of stem cell therapy for managing cirrhosis, such as discussing the selection of appropriate subtypes of bone marrow stem cells and the need for pre-differentiation into hepatocyte-like cells prior to transplantation, and providing an overview of the methods to improve cell viability and to prevent the exacerbation of cirrhosis. The role of human umbilical cord blood stem cells and amniotic epithelial cells for the treatment of liver disease will be also introduced.

show abstract

“…Secreting factors derived from these cells are assumed to induce hepatic differentiation [54]. Deng et al observed the hepatocyte-like cells after co-culture rat BM-MSCs with activated HSC.…”

Section: Induction By Soluble Growth Factors or Cytokines-defined Mediummentioning

confidence: 99%

Mesenchymal Stem Cells: Current Clinical Applications and Therapeutic Potential in Liver Diseases

Prasajak¹

2014

J Bone Marrow Res

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are one of valuable candidates for cell-based therapy which trend to be safe, feasible and promising in the treatment of several diseases. Since, MSCs possess unique biological characteristics which make them variable applying in clinic. These include self-renewal capacity, multi-lineages differentiation potential, homing and migration ability, immunomodulatory properties and paracrine secretion activity. These beneficial advantages lead to increase possibility of using MSCs in several implications such as regenerative medicine, tissue engineering, cells-based therapy and other clinical applications. At present, many clinical trials related to MSCs have been conducted in various diseases including bone defect, myocardial infarction, spinal injury, critical limb ischemia, diabetes and multiple sclerosis based on registered data at http://clinicaltrials.gov. The most of these clinical trials are being under investigation and are in phase I and II. There are several diseases of the liver that cause liver dysfunction due to hepatocytes injury and loss including viral hepatitis, fatty liver disease, drug or toxin induced liver injury, hepatocellular carcinoma, autoimmuneassociated hepatic disorders and cirrhosis. In this review, we focus on mesenchymal stem cell (MSCs) toward liver disease treatment by MSCs therapy. In this regard, we summarized characteristics of mesenchymal stem cell (MSCs) including sources, general characteristics, differentiation potential, niches, and biological effects of the cells. We also emphasized on current methods for hepatocyte differentiation and current board clinical applications. The current studies of MSCs both in preclinical and clinical trials related to liver diseases are also discussed in context of possible application in therapeutic purposes in this review. Understanding the basic knowledge of MSCs and their therapeutic capability in preclinical and clinical studies will accelerate therapeutic value of MSCs transplantations for disease treatments, drug screening, stem cell banking and regenerative medicine.

show abstract

Hepatic stellate cells modulate the differentiation of bone marrow mesenchymal stem cells into hepatocyte‐like cells

Cited by 43 publications

References 43 publications

Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma

Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma

Therapeutic Strategies of Stem Cell Transplantation for Liver Cirrhosis

Mesenchymal Stem Cells: Current Clinical Applications and Therapeutic Potential in Liver Diseases

Contact Info

Product

Resources

About